Unlocking the biology of dementia with Lewy bodies: Biomarker insights from DDC to synapses
Join us for the first in a series of webinars dedicated to promising neuro biomarkers.
Our webinar series about promising neuro biomarkers
In this first edition, Dr. Olivia Belbin and Dr. Katharina Bolsewig will discuss how DOPA Decarboxylase (DDC) and synaptic biomarkers, such as SNAP-25 and VAMP-2, are advancing our understanding of dementia and other disorders with Lewy body pathology.
You will discover the latest research on these novel biomarkers, learn how they can help differentiate between these Lewy body disorders and their mimics, and explore their potential to support both research and clinical innovation.
The speakers
Dr. Olivia Belbin
Sant Pau Research Institute in Barcelona, Spain. Focuses on development of novel diagnostic and therapeutic tools for neurodegenerative diseases and psychiatric disorders through biomarker development and mechanistic studies of synapse degeneration and inflammation.
Dr. Belbin's Neuro Biomarker Talk:
Impact of Alzheimer’s comorbidity on synaptic biomarkes in dementia with Lewy bodies.
Dr. Katharina Bolsewig
UMC, Amsterdam, the Netherlands. Focuses on fluid biomarkers for dementia with Lewy bodies, particularly their validation and the development of new assays to enhance detection and understanding of the disease.
Dr. Bolsewig's Neuro Biomarker Talk:
DOPA Decarboxylase - an emerging fluid biomarker for LBDs.
For whom this webinar is intended
This session is open for all, but was designed for the following professions engaged in neurodegenerative disease research with a focus on neurodegenerative disorders characterized by synaptic and dopaminergic dysfunction:
- Researchers
- Pharmaceutical professionals
- Biotechnology professionals
- CROs (Contract Research Organizations)
- Technology providers
